Clarient, Inc. (CLRT) – Shaping the Future of Targeted Cancer Therapy with Dr. Todd S. Barry as New Medical Director
The rise of individualized medicine is the new direction in oncology. More sophisticated and complex testing will be required to select the right therapy for the right patient at the right time in their treatment. Clarient has created a state-of-the-art commercial cancer laboratory providing the most advanced oncology testing and diagnostic services available both onsite and over the web. The Company is also developing new, proprietary "companion" diagnostic markers for therapeutics in breast, prostate, lung and colon cancers, and leukemia/lymphoma. Clarient has over 1,700 targeted cancer therapeutics in their pipeline. Todd S. Barry, M.D., Ph.D. has joined Clarient’s medical staff…